Skip to main content

Table 4 Clinical features of patients in different ALL groups before chemotherapy

From: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Clinical features ALL
  Newly Diagnosed CR Refractory & Relapsed
Sex    
Male 50 24 26
Female 34 20 19
Age (year) 31 (18-77) 29 (18-62) 27 (18-77)
WBC (×109/L) 53 (0.9-367.4) 14.75 (3.01-39.65) 25.99 (0.45-102.56)
Hb (g/L) 70 (31-143) 108 (84-394) 75 (48-139)
PLT(×109/L) 37(1-338) 105 (25-394) 45 (2-245)
Subtype T 14 T 4 T 4
B 70 B 40 B 41
Chromosome Abnormality Ph + 20 Ph + 6 Ph + 10
del (5) (p14) 2 21 + mar 1 del (5) (p14) 1
21 + mar 2   
Molecular Genetics Abnormality bcr-abl 20 bcr-abl 6 bcr-abl 10
Sternal tenderness 54/84 20/44 27/45
Lymphadenectasis 50/84 25/44 26/45
Splenohepatomegalia 45/84 21/44 23/45
Curative effect 69/84 44/44 36/45
  1. This table shows clinical features of ALL patients in different groups at the time of diagnosis. WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet. Curative effect refers to achieving complete remission after 2 courses of standard chemotherapy.